NewsRoom Articles - BioMedWire (BMW)

ThursdaySep 10, 2026 9:00 am

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ: QNTM) (Profile) has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed…

WednesdaySep 09, 2026 11:15 am

How Earth Science Tech Inc. (ETST) Is Building a Self-Sustaining Business on Strategic Vertical Integration and Dual-Segment Targeting

Earth Science Tech has made meaningful progress over the last few years, building a business anchored in a conglomerate model, infrastructure as a service, and end-to-end vertical integration The company is focused on the seamless integration of patient care through its operating businesses that offer telemedicine and telehealth infrastructure for consultations and third-party providers, compounding services, and fulfilment ETST has leveraged vertical integration to not only support the operations of its businesses but also tap into both B2B and B2C segments for revenue and growth Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine…

WednesdaySep 09, 2026 10:00 am

Expert Flags Hidden Crisis in the Way UTIs Are Diagnosed

For many women, UTIs are something they routinely experience. These usually start as a burning sensation or a sudden urge to use the bathroom. For some, there is a sudden onset of discomfort that they just cannot ignore. While many receive a dose of antibiotics after being told what’s bothering them “is just a UTI,” several questions remain in the mind of the woman. Was the sample used reliable? Did they receive the right diagnosis? Was the medical professional sure about what’s going on? These uncertainties put the issue beyond a medical one and expand it into a human issue as well. Giovanna Forte, a health tech entrepreneur…

TuesdaySep 08, 2026 11:15 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Builds Manufacturing, IND and Capital Foundation Ahead of Planned Clinical Translation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Investors in biotechnology often look for companies with a clear path toward clinical development, where regulatory preparation, manufacturing readiness and access to capital can help reduce execution risk. Onco-Innovations Ltd. is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company has strengthened its clinical foundation through manufacturing milestones, IND-enabling activities, strategic partnerships and a recent funding arrangement designed to support continued advancement of its oncology pipeline. For biotechnology investors, a…

TuesdaySep 08, 2026 9:00 am

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ: QNTM) (Profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at…

FridaySep 04, 2026 10:00 am

Timing of Brain Metastasis Predicts Survival of Colorectal Cancer Patients

A recent study that was conducted on 5,617 people diagnosed with colorectal cancer found that while it was uncommon for these patients to develop brain metastases, those patients that developed brain metastases had overall shorter survival times than other patients that didn’t develop brain metastases linked to their colorectal cancer. Out of the total study population of colorectal cancer patients, 94 (1.7%) had brain metastases that had been confirmed after radiology tests were done. The average age of the patients with brain metastases was 60. Out of those patients with brain metastases, males had a 60.6% share while the others…

FridaySep 04, 2026 9:00 am

From Molecule to Medicine: Onco-Innovations Aligns ONC010 for Clinical Development

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations has advanced ONC010 across API manufacturing, polymer optimization, analytical development, preclinical characterization and clinical planning as it works toward human evaluation. A 300-gram development batch of ONC010’s active ingredient achieved approximately 99.3% purity, while a newly identified non-tin catalyst could support improved control of impurities in future polymer manufacturing. The company is building an Australian pathway for a potential First-in-Human study while advancing bioanalytical, metabolism, ADME, toxicology, biodistribution and regulatory preparation during the second half of 2026. Cancer therapies built around DNA damage…

ThursdaySep 03, 2026 10:00 am

Administering Immunotherapy Prior to Surgery Improves Brain Cancer Treatment Outcomes

A preclinical study conducted by a joint team from Switzerland has found that treatment outcomes for glioblastoma patients improved considerably if they received immunotherapy before undergoing surgery to remove the tumors, instead of first having the tumors surgically removed and then receiving immunotherapy. The study findings appeared in the Nature Communications journal. The researchers are based at UNIGE (University of Geneva) and HUG (Geneva University Hospitals) and were led by Associate Professor Denis Migliorini, who works at UNIGE. Only a tiny fraction (5%) of glioblastoma patients survive for five or more years even after receiving existing treatments that include surgery, chemotherapy and radiotherapy. The current practice is to surgically remove as much of the brain…

TuesdaySep 01, 2026 10:00 am

Why Many Companies Are Reconsidering Coverage for GLP-1 Drugs

As GLP-1 use has exploded in the U.S., many companies have started discontinuing coverage of these treatments in the health plans they maintain for their employees. This is a trend worth watching, and it warrants a deeper look to understand why it is happening. First off, GLP-1 drugs are medicines like Wegovy and Zepbound that were designed to help in the treatment of type 2 diabetes. Many of these drugs were eventually also approved by the U.S. FDA for use in weight loss, and their use exploded. You would imagine that if these medications are being used by more and…

MondayAug 31, 2026 9:00 am

Earth Science Tech Inc. (ETST) Taps into New Verticals with Zoolzy Acquisition

Earth Science Tech recently completed the acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products The acquisition delivers value across three growth drivers, including expanding overall profit margins, broadening access to new ingredients, and enabling entry into the veterinary market The acquisition represents Earth Science Tech’s move to seize strategic opportunities that broaden the company’s telehealth and pharmacy fulfillment platforms into new, complementary verticals Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, recently acquired Zoolzy LLC. Based in Doral, Florida, where it operates from…